The international surgical journal with global reach

Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor–positive breast cancer: long-term follow-up of the BIG 1-98 Trial. J Clin Oncol 2019; 37: 105-114.

Published: 12th November 2019

Authors: Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen M-B, Ejlertson B, de Azambuja E et al.


This four way trial examined outcomes at a median of 12.6 years of follow-up; 3833 women remained in the study. For monotherapy, letrozole improved disease-free survival (hazard ratio 0.91, 95 per cent confidence interval 0.8 to 1.01). Letrozole reduced contralateral cancers for the first ten years, after which this reversed.

Pubmed Link